A live webcast of the Jefferies fireside chat can be accessed by visiting the Investors section of the Company's website at ...

The Teradata logo is a trademark, and Teradata is a registered ... Inc. , a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today ...

SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now enrolling patients d ...

Namrata has contributed to the success of multiple major FDA-approved drugs for ophthalmic diseases and has meaningfully enhanced ... ophthalmic surgery and ocular itching associated with allergic ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to improving vision in the real world through ...

Medidata, a Dassault Systèmes brand and leader of clinical trial solutions to the life sciences industry, is kicking off NEXT New York 2024, its premier life sciences conference. Uniting more than ...

The tiffin, once a humble affair with basic and traditional items, has now evolved into a more diverse and creatively packed ...

There are new concerns that phenylephrine, an ingredient in common over-the-counter cold and allergy medicines is ineffective. The FDA said the ingredient is safe but many popular medicines are ...

It is an important step in ALK’s strategic efforts to establish leading positions in anaphylaxis, food allergy, and new disease areas such as urticaria, supplementing our core allergy offerings.

The Food and Drug Administration on Thursday proposed ending the use of a common ingredient found in many popular over-the-counter cold and allergy medications. The agency said an extensive ...

The FDA is proposing many popular over-the-counter cold and allergy medications be removed from store shelves. The agency says a common ingredient they share, oral phenylephrine, doesn’t ...

Many scientists at the federal health agencies await the second Donald Trump administration with dread as well as uncertainty over how the president-elect will reconcile starkly different philosophies ...